PURPOSE: To estimate scenarios for survival for women with metastatic breast cancer (MBC) who are starting chemotherapy. PATIENTS AND METHODS: We sought randomized, first-line chemotherapy trials for MBC published from 1999 to 2009. We recorded median progression-free survival (PFS) and median overall survival (OS) and extracted the following percentiles (represented scenario) from each OS curve: 90th (worst-case), 75th (lower-typical), 25th (upper-typical), and 10th (best-case). We also estimated these scenarios for each OS curve by multiplying its median by four simple multiples: 0.25 (worst-case), 0.5 (lower-typical), 2 (upper-typical), and 3 (best-case). Estimates were deemed accurate if they were within 0.75 to 1.33 times the actual value. RESULTS: From 36 trials (13,083 women), the mean for median PFS was 7.6 months (interquartile range [IQR], 6.0 to 9.0 months), the mean for median OS was 21.7 months (IQR,18.2 to 24.0 months), and the mean for the ratio of median OS to median PFS was 3.0 (IQR, 2.4 to 3.5). The mean for each OS scenario was worst-case, 6.3 months (IQR, 4.8 to 7.5 months); lower-typical, 11.9 months (IQR, 9.9 to 13.2 months); upper-typical, 36.2 months (IQR, 31.1 to 41.3 months); and best-case, 55.8 months (IQR, 47.5 to 60.2 months). Simple multiples of the median gave accurate estimates of the worst-case scenario in 73% of OS curves, lower-typical in 97%, upper-typical in 95%, and best-case in 96%. OS was longer in trials with higher proportions of estrogen receptor-positive tumors (P = .001) and in trials of trastuzumab-treated human epidermal growth factor receptor 2-positive tumors (P = .001). CONCLUSION: Simple multiples of an OS curve's median can accurately estimate typical (half to double the median), best-case (triple the median), and worst-case (one quarter of the median) scenarios for survival.
PURPOSE: To estimate scenarios for survival for women with metastatic breast cancer (MBC) who are starting chemotherapy. PATIENTS AND METHODS: We sought randomized, first-line chemotherapy trials for MBC published from 1999 to 2009. We recorded median progression-free survival (PFS) and median overall survival (OS) and extracted the following percentiles (represented scenario) from each OS curve: 90th (worst-case), 75th (lower-typical), 25th (upper-typical), and 10th (best-case). We also estimated these scenarios for each OS curve by multiplying its median by four simple multiples: 0.25 (worst-case), 0.5 (lower-typical), 2 (upper-typical), and 3 (best-case). Estimates were deemed accurate if they were within 0.75 to 1.33 times the actual value. RESULTS: From 36 trials (13,083 women), the mean for median PFS was 7.6 months (interquartile range [IQR], 6.0 to 9.0 months), the mean for median OS was 21.7 months (IQR,18.2 to 24.0 months), and the mean for the ratio of median OS to median PFS was 3.0 (IQR, 2.4 to 3.5). The mean for each OS scenario was worst-case, 6.3 months (IQR, 4.8 to 7.5 months); lower-typical, 11.9 months (IQR, 9.9 to 13.2 months); upper-typical, 36.2 months (IQR, 31.1 to 41.3 months); and best-case, 55.8 months (IQR, 47.5 to 60.2 months). Simple multiples of the median gave accurate estimates of the worst-case scenario in 73% of OS curves, lower-typical in 97%, upper-typical in 95%, and best-case in 96%. OS was longer in trials with higher proportions of estrogen receptor-positive tumors (P = .001) and in trials of trastuzumab-treated humanepidermal growth factor receptor 2-positive tumors (P = .001). CONCLUSION: Simple multiples of an OS curve's median can accurately estimate typical (half to double the median), best-case (triple the median), and worst-case (one quarter of the median) scenarios for survival.
Authors: Anuradha Vasista; Martin Stockler; Andrew Martin; Nick Pavlakis; Katrin Sjoquist; David Goldstein; Sanjeev Gill; Vikram Jain; Geoffrey Liu; George Kannourakis; Yeul Hong Kim; Louise Nott; Stephanie Snow; Matthew Burge; Dean Harris; Derek Jonker; Yu Jo Chua; Richard Epstein; Antony Bonaventura; Belinda Kiely Journal: Oncologist Date: 2019-04-01
Authors: B E Kiely; G McCaughan; S Christodoulou; P J Beale; P Grimison; J Trotman; M H N Tattersall; M R Stockler Journal: Support Care Cancer Date: 2012-06-21 Impact factor: 3.603
Authors: Katrin M Sjoquist; Lindsay A Renfro; R John Simes; Niall C Tebbutt; Stephen Clarke; Matthew T Seymour; Richard Adams; Timothy S Maughan; Leonard Saltz; Richard M Goldberg; Hans-Joachim Schmoll; Eric Van Cutsem; Jean-Yves Douillard; Paulo M Hoff; Joel Randolph Hecht; Christophe Tournigand; Cornelis J A Punt; Miriam Koopman; Herbert Hurwitz; Volker Heinemann; Alfredo Falcone; Rainer Porschen; Charles Fuchs; Eduardo Diaz-Rubio; Enrique Aranda; Carsten Bokemeyer; Ioannis Souglakos; Fairooz F Kabbinavar; Benoist Chibaudel; Jeffrey P Meyers; Daniel J Sargent; Aimery de Gramont; John R Zalcberg Journal: J Natl Cancer Inst Date: 2018-06-01 Impact factor: 13.506
Authors: Jennifer A Shin; Amanda Parkes; Areej El-Jawahri; Lara Traeger; Helen Knight; Emily R Gallagher; Jennifer S Temel Journal: Palliat Med Date: 2016-03-15 Impact factor: 4.762
Authors: Andrew J Bishop; Joe Ensor; Stacy L Moulder; Simona F Shaitelman; Mark A Edson; Gary J Whitman; Sandra Bishnoi; Karen E Hoffman; Michael C Stauder; Vicente Valero; Thomas A Buchholz; Naoto T Ueno; Gildy Babiera; Wendy A Woodward Journal: Cancer Date: 2015-09-08 Impact factor: 6.860
Authors: Gabriel A Brooks; Angel M Cronin; Hajime Uno; Deborah Schrag; Nancy L Keating; Jennifer W Mack Journal: J Palliat Med Date: 2015-11-24 Impact factor: 2.947